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Oxytocin (OT) is an exciting potential therapeutic agent, but it is highly sensitive to 
modification and suffers extensive degradation at elevated temperature and in vivo. Here we 
report studies towards OT analogs with favorable selectivity, affinity and potency towards the 
oxytocin receptor (OTR), in addition to improving stability of the peptide by bridging the 
disulfide region with substituted dibromo-xylene analogs. We found a sensitive structure-
activity relationship in which meta-cyclized analogs (dOTmeta) gave highest affinity (50 nM 
Ki), selectivity (34-fold), and agonist potency (34 nM EC50, 87-fold selectivity) towards 
OTR. Surprisingly, ortho-cyclized analogs demonstrated OTR and vasopressin V1a receptor 
subtype affinity (220 nM and 69 nM, respectively) and pharmacological activity (294 nM and 
35 nM, respectively). V1a binding and selectivity for ortho-cyclized peptides could be 
improved 6-fold by substituting a neutral residue at position 8 with a basic amino acid, 
providing potent antagonists (14 nM IC50) that displayed no activation of the OTR. 
Furthermore, xylene-bridged analogs demonstrated increased stability compared to OT at 
elevated temperature, demonstrating promising therapeutic potential for these analogs which 
warrants further study. 
 
Key words: Oxytocin, Disulfide bridging, Cyclic peptides, Peptide-based drugs, Increased 
stability 
 
1. Introduction 
Oxytocin (OT), a nonapeptide released from the pituitary gland, is a promising therapeutic 
agent that is heavily involved with lactation and uterine contraction in the peripheral system 
and is further linked with complex neurological disorders in the central nervous system. For 
example, OT is the World Health Organization’s recommended drug to prevent postpartum 
hemorrhaging, which is one of the most common causes of maternal morbidity.
1-2
 However, 
OT suffers from limited stability in aqueous solution that is especially problematic in 
subtropical climates where the majority of maternal deaths occur.
3-6
 Further, OT is highly 
susceptible to metabolic degradation, having an in vivo half-life of 3 min, causing substantial 
loss of activity.
7
 
Common approaches to overcome peptide degradation, including use of unnatural and D-
amino acids, terminal capping and chemical modification or mutation of the proteolytic 
recognition sites, are often unsuitable for OT since its biological activity is highly sensitive to 
  
structural change. This is because OT shares a molecular structure closely related to 
vasopressin (also known as arginine vasopressin, AVP), making the development of a highly 
specific and stable oxytocin receptor (OTR) ligand challenging. Both OT and AVP contain a 
disulfide bridge between residues 1 and 6, resulting in a structure containing a cyclic core 
comprising six amino acids with a flexible three-residue amidated tail (Figure 1, Table 1). 
The peptides differ by the amino acids at position 3, and at position 8 whereby OT-related 
peptides contain a neutral residue, while AVP peptides bear a basic amino acid. This subtle 
difference in polarity at position 8 is thought to confer the molecules’ interaction with its 
receptor that, in turn, is related to its distinctive function.
8-9
 However, due to their common 
structure, OT and AVP peptides bind to and act on multiple members of the G-protein 
coupled receptor family to exert their pharmacological effects, including OTR, and AVP 
receptor subtypes V1a, V1b and V2.
10
 For OT, Tyr2 and Asn5 are fundamental for activity in 
the uterus while residues Leu8, Pro7, Gln4 and Ile3 are key for receptor binding.
11
 
  
Figure 1. Structure of therapeutic peptide OT, AVP and related analogs, with variables 
presented alongside in Table 1 
Specifically, to improve the stability of OT two main strategies have been used (i) N-
terminal deamination,
12-13
 and (ii) disulfide bond engineering, since the disulfide bond is 
generally not implicated in OTR binding or activity. In the case of disulfide engineering, a 
variety of modifications at this position have been investigated, typically replacing the 
disulfide bridge with alternatives including thioether,
14
 carbon,
15-16
 lactam,
17
 and diselenide 
bridges.
18
 Structure activity relationships (SARs) have identified that introduction of one 
alternative atom on the disulfide bond (such as selenium) causes a subtle change in the ring 
region of OT that is tolerated for OTR binding and efficacy,
15, 19
 while reductions in the ring 
size of OT can abolish OTR activity. However, the majority of studies omit determination of 
AVP receptor subtype activity, leaving a question over alterations in receptor selectivity 
induced by these chages.
19
 Alternatively, carbetocin, an OT mimetic with an improved 
pharmacokinetic profile and prolonged uterotonic activity,
14
 shows reduced selectivity and 
affinity towards the OTR (10-fold lower than OT), and is only a OTR partial agonist (Figure 
1).
20-21
 In addition, recent reports have emerged that suggests carbetocin is also a V1a and V1b 
antagonist, complicating its pharmacological profile.
22
 
In a complementary and relatively less studied approach to disulfide engineering, disulfide 
bridging represents an attractive alternative that circumvents the lengthy and complex 
synthesis of unnatural cyclized peptides through engineering strategies. For example, Collins 
Peptide R1 R2 X Y Z 
OT Leu Ile H NH2 S 
dOT Leu Ile H H S 
AVP Arg Phe H NH2 S 
dOT(L8R) Arg Ile H H S 
carbetocin Leu Ile CH3 H CH2 
  
et al. recently demonstrated that a maleimide-functionalized polymer could successfully 
bridge the disulfide region of OT, resulting in a conjugate with increased thermal stability.
23
 
In the present study, we investigated the biological activity and stability of OT analogs 
bridged by dibromo-xylene molecules that offer an irreversible covalent modification. 
Previously, dibromo-xylenes have been used to assist peptide cyclisation,
24
 and increase 
proteolytic stability or helicity of peptides,
25-26
 with further applications in the construction of 
protein mimics.
27
 Furthermore, a range of substituted analogs are available commercially, 
enabling bridging distance structure-activity relationships (SAR) to be studied. We produced 
a library of cyclized OT analogs based on N-terminally deaminated OT (dOT), which has 
been reported to have increased stability compared to OT.
7
 In addition, omission of a N-
terminal amine on dOT prevented any complications from competing side reactions during 
cyclization. The peptide library was screened for binding affinity, biological activity and 
stability at elevated temperature using in vitro assays, revealing promising potency, 
selectivity and stability profiles driven by xylene-bridging in OT analogs. 
2. Results and discussion 
2.1 Synthesis of OT and peptide analogs 
Native OT, deaminated OT (dOT) and dOT(L8R) were successfully synthesized via 
automated fluorenylmethoxycarbonyl (Fmoc) solid phase peptide synthesis (SPPS), and 
coupling with 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU). In the case of dOT and dOT(L8R), a deaminated protected cysteine was made by 
reacting triphenylmethylchloride in dicholomethane with 3-mercaptopropionic acid
28
, then 
coupled in the final position. Peptides were cleaved from the resin using trifluoroacetic acid 
(TFA) in the presence of 2.5% DTT to prevent oxidation of cysteine or deaminated cysteine 
residues. Crude peptides were purified by reverse phase (RP) liquid chromatography mass 
spectrometry (LC-MS) using either water/methanol or water/acetonitrile (MeCN). When 
required, cyclization of native disulfide bonds was achieved by stirring the peptide in 
ammonium bicarbonate buffer in the presence of oxygen for up to three days.  Both purified 
peptides were lyophilized, and characterized by RP LC-MS (Supplementary Fig. 1.1), which 
is presented in Table 2.    
 
2.2 Disulfide bridging of dOT with xylene analogs 
Cyclization of dOT analogs using various isomers of dibromoxylene was first attempted in a 
mixture of ammonium bicarbonate and acetonitrile, at room temperature and at a final 
concentration of 1 mM peptide. While full conversion was seen after 10 min, a small 
proportion of polymerized product for both meta- (11 %) and para- (21 %) dibromoxylene-
cyclized dOT was detected. Pleasingly, this side product was removed when the reaction was 
performed at higher dilution (0.5 mM) and lower dibromoxylene molar equivalents (1.1 
equivalents vs. 3 equivalents), affording all peptides efficiently and in good overall yield 
(Table 2, Figure 2). Xylene-bridged analogs showed reduced solubility in water; addition of 
15% v/v DMSO solved this issue. 
  
Table 2. Characterization data and yields for OT peptide analogs. 
Peptide MW (Da) Rt (min) ES peaks (m/z) Yield (%)c 
OTcy 1006.4 9.64
a 1007.90 (m+1) 18 
dOToc 993.4 11.82
a 994.72 (m+1) 21 
dOTcy 991.4 11.74
a 992.61 (m+1) 17 
dOT(L8R)oc 1037.2 9.71
a 1038.67 (m+1) 24 
dOTmeta 1095.5 14.19
a 1096.67 (m+1) 16 
dOTpara 1095.5 14.24
a 1096.67 (m+1) 16 
dOTortho 1095.5 14.05
a 1096.67 (m+1) 18 
dOT(L8R)ortho 1139.4 8.72
b 1140.48 (m+1) 20 
a LCMS analytical Method 1 used to analyze peptide (please refer to Experimental Section 3.3 for details) 
b LCMS analytical Method 2 used to analyze peptide 
c Yields are calculated based on resin load  
Key: d = deaminated; cy = cyclized; oc = open chain; meta = meta-xylene bridged; para = para-xylene bridged; 
ortho = ortho-xylene bridged.   
 
Figure 2. Conjugation reaction with substituted dibromo-xylene reagents to form disulfide 
bridged analogs. 
 
2.3 Binding affinity of peptides against OTR and AVP receptor subtypes 
The OTR has a substantial reliance on cholesterol for proper functioning that has, in turn, 
presented severe challenges to attempts to generate a crystal structure of the OT-OTR 
complex.
29
 Further, common problems facing solubilized OTR include reductions in affinity 
and loss of characteristic binding properties towards ligands. Therefore, SAR for OT analogs 
is best determined using in vitro receptor binding studies, with conclusive studies also testing 
against AVP receptor subtypes to address selectivity. Inhibitory constant (Ki) values for 
human receptors are presented in Table 3. Displacement of either [
3
H]OT or [
3
H]AVP by 
dOT analogs was measured over a concentration range of 0.95-30000 nM, while non-specific 
binding of peptide analogs was defined using the appropriate cold endogenous peptide.
30
 
Receptor specificity was calculated by comparing the affinity of ligands to members of the 
OT and the AVP receptor family member that demonstrated the highest binding capacity.  
While all analogs screened suffered a decrease in binding affinity toward the OTR compared 
to native OT, selectivity over the AVP receptor subtypes was improved for dOTmeta and 
maintained for the dOTpara derivative (Table 3, Figure 3a). Further, meta-cyclization 
demonstrated the highest affinity for OTR binding among the analogues tested. Interestingly, 
dOTortho showed high affinity and preferential binding towards V1a receptor (Figure 3b). The 
  
introduction of a basic residue at position 8 further enhanced the affinity and selectivity 
profile for analog dOT(L8R)ortho towards V1a receptor compared to both dOTortho and AVP.  
Table 3. Peptide inhibition constants (Ki in nM) and selectivity profile. 
Ki (nM) Receptor selectivity 
Peptide OTR V1a V1b V2 OTR
a V1a
b 
OT 1.2 ± 0.3 20 ± 3 >6000 >6000 17 0.06 
AVP 6 ± 1 2 ± 0.3 2 ± 0.6 32 ± 4 0.3 3.0 
dOTmeta 50 ± 14 1681 ± 13 >6000 >6000 34 0.03 
dOTpara 142 ± 12 1954 ± 8 >6000 >6000 14 0.07 
dOTortho 220 ± 10 69 ± 12 >6000 >6000 0.3 3.2 
dOT(L8R)ortho 166 ± 19 30 ± 6 >6000 >6000 0.2 5.5 
a
 Calculated by dividing strongest AVP receptor subtype binding value with OTR value 
b
 Calculated by dividing OTR binding value with V1a value
 
Binding of OT, AVP and xylene-bridged analogs to human OT/AVP receptor subtypes. Values are the mean 
value of three different experiments, each performed in duplicate.  
 
Figure 3. Binding of xylene-bridged dOT analogs to human OTR or V1a receptor subtypes 
measured in a competition binding assay.  
2.3 Biological activity of peptides by calcium flux assay 
OT/AVP peptides exert their biological function through binding to the relevant receptor, 
causing a measurable increase in intracellular Ca
2+ 
in a fluorescence assay.
29-30
 Half-maximal 
effective concentration (EC50) values or functional antagonism (half-maximal inhibitory 
concentration, IC50) for the peptide series is reported in Table 4. In addition to receptor 
binding, dOTmeta and dOTpara showed excellent agonist potency (EC50) and selectivity 
towards OTR. In agreement with affinity measurements, dOTmeta was the most potent and 
selective OTR agonist, however maximal activation was 75  1%, suggesting that dOTmeta is 
a partial agonist (Figure 4a), but nevertheless more effective than carbetocin (45  6%).22 
Surprisingly, dOTortho showed agonist activity towards OTR and antagonist activity towards 
V1a receptor. This phenomenon has been shown recently for carbetocin, which displays 
agonistic behavior towards OTR and antagonism towards the V1a and V1b receptors.
22
 
Alternatively, a complete switch in receptor selectivity was demonstrated for analog 
dOT(L8R)ortho that displayed potent antagonist activity and selectivity towards the V1a 
receptor (Figure 4b), showing no activation of OTR.  
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We demonstrate here that dOTmeta is a selective human OTR agonist with no 
antagonist activity towards the OTR detected, while dOT(L8R)ortho was identified as a 
selective V1a receptor antagonist. Whilst these data demonstrate that high affinity and 
selective binders can be achieved through disulfide bridging, modification to the OT 
backbone significantly influences affinity, selectivity and potency. The sensitivity of OT to 
alterations in ring size emphasizes the importance of screening multiple receptor subtypes 
when exploring OT ring modifications due to the complex pharmacological profile of this 
hormone. We hypothesize that modification of the disulfide bond distorts the cyclic region of 
these analogs, which influences their interaction with OT/AVP receptor subtypes.  
Table 4. Peptide agonist (EC50 in nM), antagonist (IC50 in nM) and selectivity profile. 
Agonist; EC50 Receptor selectivity 
Peptide OTR V1a V1b V2 OTR
a V1a
b 
OT 0.3 ± 0.1 9 ± 2 33 ± 7  29 ± 5 30 0.03 
dOTmeta 34 ± 6 >20000 2966 ± 120 3900 ± 350 87 - 
dOTpara 109 ± 24 >20000 2223 ± 533 3669 ± 146 20 - 
dOTortho 294 ± 58 >20000 8302 ± 1982 10764 ± 101 28 - 
dOT(L8R)ortho >10000 >20000 9263 ± 957 18919 ± 146 - - 
Antagonist; IC50 Receptor selectivity 
Peptide OTR V1a V1b V2 OTR V1a 
dOTmeta agonist 4400 agonist agonist - - 
dOTpara agonist 7862 agonist agonist - - 
dOTortho agonist 35 ± 28 agonist agonist - 8.4
c 
dOT(L8R)ortho 1724 ± 177 14 ± 8 agonist agonist 0.008 123 
a
 Calculated by dividing strongest AVP receptor subtype binding value with OTR value 
b
 Calculated by dividing OTR subtype agonist value with V1a antagonist value 
c
 Calculated by dividing OTR subtype binding value with V1a value 
Pharmacology profile of OT, AVP and xylene-bridged analogs to human OT/AVP receptor subtypes. Values are 
the mean value of three different experiments, each performed in duplicate.  
 
Figure 4. Function agonism or antagonism of xylene-bridged dOT analogs to human OTR or 
V1a receptor subtypes measured in a competition assay.  
2.4 Thermal Stability 
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The formation of a non-reversible covalent linkage in place of a disulfide bond is expected to 
improve the stability of OT analogs since previous research suggests that reactions involving 
this region plays a central role for OT degradation, being prone to oxidation, dimerization, 
and -elimination.6 Peptide stability was investigated through an accelerated stability test in 
which dOTmeta was compared to OT, as a representative analog of the bridged peptides. 
Peptides were dissolved in water to a concentration of 0.5 mg mL
-1 
and heated to 50 C in a 
heat block for 10 days. After this time aliquots were removed and analyzed by RP-LCMS. 
The amount of remaining peptide was calculated as a percentage of the relevant peak 
remaining before heat exposure. In this study, degradation was prevented by conjugation of 
dibromo-xylene (Figure 5). 
 
Figure 5. Degradation of aqueous solutions of native OT and dOTmeta conjugates at 50 C.  
3 Conclusions 
We report rapid and effective synthesis of xylene-bridged analogs of dOT and determined the 
impact on biological activity and stability following modification. This flexible approach 
facilitated access to a variety of isomeric xylene bridges, which led to diverse modulation of 
receptor selectivity, potency and affinity, presenting an alternative pharmacological profile 
and therapeutic potential to OT.  A key finding from this work was that ring size and 
geometry influenced OTR binding, with meta-bridged analogs demonstrating the most 
favorable binding and pharmacology profile towards OTR. dOTmeta demonstrated an 
improved selectivity profile for both binding and activation towards the OTR and showed 
minimal V1a antagonist activity, a more selective pharmacological than the widely used drug 
carbetocin.
22, 31
 It was surprising that dOTortho displayed preferential binding affinity and 
selectivity towards V1a, which can function as both a OTR agonist and V1a antagonist, which 
could be further enhanced for dOT(L8R)ortho, incorporating a basic residue at position 8, a 
mutation important for AVP receptor engagement. Notably, dOT(L8R)ortho displayed 
improved binding selectivity towards V1a over AVP, with substantial antagonist activity only 
towards this receptor subtype.  
OT binds and activates OTR, V1a and V1b receptor subtypes, which has contributed to limited 
or debated efficacy in clinical practice.
32-33
 The molecules reported here have a defined 
binding and pharmacology profile, making them potentially useful tools for probing the 
pharmacological potential of OTR. Furthermore, xylene-bridging proved useful in enhancing 
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thermal stability, demonstrating minimal degradation compared to native OT at elevated 
temperatures. Consequently, the xylene bridged analogs represent an interesting modification 
to OT with increased stability, worthy of further investigation. 
4 Experimental 
4.1 Materials  
General laboratory chemicals, were obtained from Sigma-Aldrich Chemical Co. and used 
without further purification. Rink amide Tentagel resin (0.71 mmol/g) was obtained from 
Rapp Polymere while N,N-dimethylformamide (DMF), N-Methyl-2-pyrrolidone (NMP), 
piperidine and trifluoroacetic acid (TFA) were obtained from Merck Millipore. Fmoc 
(Fluorenylmethoxycarbonyl)-L-amino acids, HBTU, N,N-Diisopropylethylamine (DIPEA) 
were purchased from AGTC bioproducts. Gases were from BOC. Solutions and buffers were 
prepared with Ultra-pure water obtained from a Millipore Elix Q-guard purification system. 
4.2 Equipment 
Peptides were purified and analysed on a Waters LC-MS system consisting of i) Waters 2767 
autosampler for samples injection and collection; ii) Waters 515 HPLC pump to deliver the 
mobile phase to the source; iii) Waters 3100 mass spectrometer with ESI; and, iv) Waters 
2998 Photodiode Array (detection at 200–600 nm)), equipped with XBridge C18 reverse-
phase columns with dimensions 4.6 mm × 100 mm for analytical and 19 mm × 100 mm for 
preparative runs. Solvents were degassed with helium and supplemented with 0.1 % formic 
acid prior to use. 
4.3 Solid phase peptide synthesis 
Peptides were synthesised using automated solid-phase peptide synthesis with Rink amide 
Tentagel resin on a ResPep SL apparatus (Intavis) using the supplied Multipep software. 
Synthesis was carried out in peptide synthesis grade DMF. Resin (20 mol/well) was swelled 
in DMF for 30 min before synthesis. Subsequent steps were conducted automatically. N-α-
amino Fmoc groups were deprotected using 20 % (v/v) piperidine in DMF (400 μL, 2 × 
5 min). The Fmoc-protected amino acid (100 μmol, 5.0 eq.; 200 μL of 0.5 M stock solution in 
NMP) for coupling was pre-activated with HBTU (95 μmol, 4.75 eq.; 190 μL of 0.5 M stock 
solution in NMP) and NMM (200 μmol, 10 eq.; 50 μL of 4 M stock solution in NMP). 
Coupling was allowed to take place over 30-55 min and amino acids were ‘double-coupled’ 
(i.e. the coupling step was repeated). To prevent deletion sequences, any unreacted N-
terminal amines were acetylated with ‘capping mixture’ (400 μL of 5 % (v/v) Ac2O in DMF) 
for 10 min. The resin was washed with DMF (3 × 1 mL) between the deprotection, coupling 
and acylation steps. The typical cycle was repeated until the final (N-terminal) amino acid 
coupling, when N-α-Fmoc deprotection at the final residue undertaken under usual 
conditions. Following synthesis, peptides were washed several times (3 × 1 mL DMF, 3 × 
1 mL DCM, 3 × 1 mL MeOH, 3 × 1 mL Et2O) and dried overnight in a desiccator. For the 
deprotection and cleavage of all peptides, a mixture of 1.5 mL TFA:H2O:DTT:TIS 
(94:2.5:2.5:1) was added to resin bound peptide for 3 h. Crude peptides were precipitated 
using ice cold TBME, centrifuged at 4000 rpm for 15 min at 4 
°
C, and the supernatant 
  
discarded. The remaining peptides were washed with a fresh aliquot of TBME and the 
process repeated. Precipitate was dried in a desiccator over silica gel to yield off white solids 
which were dissolved in a H2O:MeOH mixture for purification by RP LC-MS. Following 
purification, fractions containing pure peptide were combined and concentrated in the 
Genevac. Subsequently, pure peptides were re-dissolved in water and freeze-dried overnight. 
4.4 Purification and characterization 
LC-MS Analytical gradient 1: 5 % to 98 % MeOH in H2O over 10 min, 98 % MeOH was 
held for 2 min, MeOH was reduced from 98 % to 5 % over 1 min, and held at 5 % until 
18 min. LC-MS Analytical gradient 2: 5 % to 98 % MeCN in H2O over 10 min, 98 % MeCN 
was held for 2 min, MeCN was reduced from 98 % to 5 % over 1 min, and held at 5 % until 
18 min.  LC-MS semi-preparative gradient: 5 % to 25 % MeOH in H2O over 1 min, then 
increased to 75 % MeOH over 10 min. MeOH was further increased to 98 % over 1 min, held 
at 98 % MeOH for 1 min, then reduced to 5 % MeOH over 1 min where it was held for 4 min 
(18 min total). 
4.5 Peptide modification 
4.5.1 S-S disulfide bridging 
Cyclization between internal cysteine residues was mediated in ammonium bicarbonate 
buffer (0.1 M, pH 8) at a final peptide concentration of 0.1 mg/mL. The solution was stirred 
for up to 3 days in the presence of oxygen at room temperature, after which time the solution 
was concentrated then lyophilized to yield pure peptide. 
4.5.2 Xylene bridging of cysteine residues 
A solution of dibromo-xylene (1.1 eq.; 0.55 mL from a 10 mM stock in MeCN) was added 
dropwise to a solution of dOT peptide in a mixture of ammonium bicarbonate (0.02 M, 
pH 7.8) and MeCN (3:1 respectively), affording an overall peptide concentration of 
0.5 mg/ml. The resulting solution was agitated at room temperature for 30 min, and peptide 
products were purified and stored as a solution of water with 15% v/v DMSO.  
4.6 Stability studies 
Peptides were dissolved in water to a concentration of 0.5 mg mL
-1 
and incubated at 50 C. 
Aliquots of the samples were removed after 10 days and analysed after direct injection (2 × 
20 μL injection) by LC-MS.  
4.7 In vitro studies 
4.7.1 Membrane preparation 
Human receptors were cloned by RT-PCR from total human liver RNA (V1a), kidney RNA 
(V2), or mammary gland RNA (OTR). Cell membranes were prepared from HEK293 cells 
transiently transfected with expression vector coding for human V1a, human V2, or mouse 
V1a. For human OTR membrane preparation, a stable HEK clone expressing the receptor was 
selected. The transient or stable cells were grown in 20 L fermenters. For each receptor, 50 g 
of cell pellet was resuspended in 30 mL of ice cold lysis buffer (50 mM HEPES, 1 mM 
  
EDTA, and 10 mM MgCl2 adjusted to pH 7.4, with the addition of complete cocktail of 
protease inhibitor (Roche Diagnostics) and homogenised with Polytron for 1 min. The 
preparation was centrifuged 20 min at 500 g at 4 °C, the pellet discarded, and the supernatant 
centrifuged for 1 h at 43 000 g at 4 °C (19 000 rpm). The pellet was resuspended in lysis 
buffer and sucrose (10%). The protein concentration was determined by the Bradford method 
and aliquots stored at −80 °C until use.  
4.7.2 Binding Affinity Measurement 
For vasopressin receptor binding studies, 60 mg of yttrium silicate SPA beads (Amersham) 
were mixed with an aliquot of membrane in binding buffer (50 mM Tris, 120 mM NaCl, 
5 mM KCl, 2 mM CaCl2, and 10 mM MgCl2) for 15 min with mixing. 50 μL of 
bead/membrane mixture was then added to each well of a 96 well plate, followed by 50 μL of 
4 nM 3H-AVP (American Radiolabeled Chemicals). For total binding measurements, 100 μL 
of binding buffer was added to the respective wells; for nonspecific binding, 100 μL of 
8.4 mM cold vasopressin or cold oxytocin for hOTR was added; and for compound testing, 
100 μL of a serial dilution of each compound in 2% DMSO was added. The plate was 
incubated for 1 h at room temperature, centrifuged 1 min at 1000 g, and counted on a Packard 
Top-Count.  
Binding to human OTR was measured by filtration binding using 1 nM 
3
H-OT final 
concentration in 50 mM Tris, 5 mM MgCl2, and 0.1% BSA (pH 7.4) buffer containing 
membranes. After compound addition as described above and 1 h of incubation at room 
temperature, the binding was terminated by rapid filtration under vacuum through GF/C 
filters, presoaked for 5 min with assay buffer, and washed 5 times with ice-cold assay buffer 
before counting. Nonspecific binding counts were subtracted from each well and data 
normalized to the maximum specific binding set at 100%. Ki values were calculated using the 
Cheng−Prussoff equation. Saturation binding experiments performed for each assay indicated 
that a single homogeneous population of binding sites was being labeled. For receptor 
binding affinity (Ki) determination, compounds were tested at least 3 times in duplicate.  
4.7.3 Stable Cell Culture and Calcium Flux Assay using Fluorescent Imaging 
  
CHO cells were stably transfected with expression plasmids encoding one of the human 
receptor of interest and grown in F-12 K, containing 10% fetal bovine serum, 1% 
penicillin−streptomycin, 1% L- glutamate, and 200 μg/mL geneticin at 37 °C in a 10% CO2 
incubator at 95% humidity. Cells were plated for 24 h at 50,000 cells/well in clear bottomed 
96 well plates and were dye loaded for 60 min with 2 μM Fluo-4-AM in assay buffer. After 
cell washing, the plate was loaded on a fluorometric imaging plate reader (FLIPR), 
compound dilution series added to the cells, and the calcium signal recorded for 5 min in 
order to detect agonist activity. After 20 min of incubation with compound, a concentration 
natural agonist (oxytocin or AVP depending on the receptor) giving 80% of the maximum 
signal was added to the plate and the calcium signal recorded for 5 min in order to detect 
antagonist activity of the test compound.  
The calcium signal reduction due to the antagonist activity of the compounds was fitted to a 
single site competition equation with variable slope and formula Y=Bottom + (Top-
Bottom)/(1+10^((LogIC50-X)*HillSlope)), where Y is the % normalized fluorescence, 
Bottom is the minimum Y, Top is the maximum Y, IC50 is the concentration inhibiting 50% 
of the agonist induced fluorescence, X is the logarithm of the concentration of the competing 
compound, and Hillslope the Hill coefficient. All compounds were tested at least 3 times in 
duplicate 
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

•Unique SAR discovered for xylene-bridged oxytocin peptide analogs  
• Affinity, selectivity and potency influenced by bridging distance  
• Meta bridged analogs demonstrate most favourable profile towards oxytocin receptor  
• Selective V1a receptor binding and potency demonstrated for ortho-bridged analogs  
• Disulphide bridging enhanced stability of peptides at elevated temperature  
 
